256 related articles for article (PubMed ID: 29027642)
1. Familial MPN Predisposition.
Tashi T; Swierczek S; Prchal JT
Curr Hematol Malig Rep; 2017 Oct; 12(5):442-447. PubMed ID: 29027642
[TBL] [Abstract][Full Text] [Related]
2. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms.
Rumi E; Cazzola M
Br J Haematol; 2017 Sep; 178(5):689-698. PubMed ID: 28444727
[TBL] [Abstract][Full Text] [Related]
3. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
4. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms.
Jäger R; Harutyunyan AS; Rumi E; Pietra D; Berg T; Olcaydu D; Houlston RS; Cazzola M; Kralovics R
Am J Hematol; 2014 Dec; 89(12):1107-10. PubMed ID: 25196853
[TBL] [Abstract][Full Text] [Related]
5. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J
Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426
[TBL] [Abstract][Full Text] [Related]
6. JAK2 haplotype 46/1 and JAK2 V617F allele burden in MPN: New evidence against the "hypermutability" hypothesis?
Stolyar MA; Klimova OA; Gorbenko AS; Brenner EV; Titov SE; Ivanov MK; Olkhovskiy IA
Int J Lab Hematol; 2018 Feb; 40(1):e8-e10. PubMed ID: 29134760
[No Abstract] [Full Text] [Related]
7. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.
De Roeck L; Michaux L; Debackere K; Lierman E; Vandenberghe P; Devos T
Hematology; 2018 Dec; 23(10):785-792. PubMed ID: 29993347
[TBL] [Abstract][Full Text] [Related]
8. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Kilpivaara O; Mukherjee S; Schram AM; Wadleigh M; Mullally A; Ebert BL; Bass A; Marubayashi S; Heguy A; Garcia-Manero G; Kantarjian H; Offit K; Stone RM; Gilliland DG; Klein RJ; Levine RL
Nat Genet; 2009 Apr; 41(4):455-9. PubMed ID: 19287384
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of myeloproliferative neoplasms.
Skoda RC; Duek A; Grisouard J
Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
[TBL] [Abstract][Full Text] [Related]
10. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
11. MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients.
Trifa AP; Bănescu C; Bojan AS; Voina CM; Popa Ș; Vișan S; Ciubean AD; Tripon F; Dima D; Popov VM; Vesa ȘC; Andreescu M; Török-Vistai T; Mihăilă RG; Berbec N; Macarie I; Coliţă A; Iordache M; Cătană AC; Farcaș MF; Tomuleasa C; Vasile K; Truică C; Todincă A; Pop-Muntean L; Manolache R; Bumbea H; Vlădăreanu AM; Gaman M; Ciufu CM; Popp RA
Am J Hematol; 2018 Jan; 93(1):100-106. PubMed ID: 29047144
[TBL] [Abstract][Full Text] [Related]
12. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.
Soler G; Bernal-Vicente A; Antón AI; Torregrosa JM; Caparrós-Pérez E; Sánchez-Serrano I; Martínez-Pérez A; Sánchez-Vega B; Vicente V; Ferrer-Marin F
Ann Hematol; 2015 May; 94(5):789-94. PubMed ID: 25482455
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
O'Sullivan J; Mead AJ
Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
[TBL] [Abstract][Full Text] [Related]
14. Germline genetic factors in the pathogenesis of myeloproliferative neoplasms.
Bellanné-Chantelot C; Rabadan Moraes G; Schmaltz-Panneau B; Marty C; Vainchenker W; Plo I
Blood Rev; 2020 Jul; 42():100710. PubMed ID: 32532454
[TBL] [Abstract][Full Text] [Related]
15. JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.
Ciboddo M; Mullally A
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):110-117. PubMed ID: 30504299
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pathogenesis of Myeloproliferative Neoplasms.
Rolles B; Mullally A
Curr Hematol Malig Rep; 2022 Dec; 17(6):319-329. PubMed ID: 36336766
[TBL] [Abstract][Full Text] [Related]
17. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
18. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
19. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
[TBL] [Abstract][Full Text] [Related]
20. Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms.
Braunstein EM; Imada E; Pasca S; Wang S; Chen H; Alba C; Hupalo DN; Wilkerson M; Dalgard CL; Ghannam J; Liu Y; Marchionni L; Moliterno A; Hourigan CS; Gondek LP
Leukemia; 2023 Mar; 37(3):627-635. PubMed ID: 36543879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]